吉-巴雷综合征和COVID-19疫苗接种:系统性审查和元分析
Stefano Censi1, Giandomenico Bisaccia1, Sabina Gallina1
1Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Via Luigi Polacchi 11, 66100, Chieti, Italy.
Journal of neurology
|January 17, 2024
概括
与mRNA疫苗相比,腺病毒载体COVID-19疫苗的Guillain-Barré综合征 (GBS) 风险更高.与mRNA疫苗相比,腺病毒载体COVID-19疫苗的风险更高. 需要进一步的研究来了解腺病毒载体疫苗是如何触发GBS的.
科学领域:
- 神经学 神经学
- 疫苗学 疫苗学 疫苗学
- 流行病学 流行病学
背景情况:
- 报告显示,与COVID-19疫苗接种相关的吉林巴雷综合征 (GBS) 病例.
- 了解与不同疫苗技术相关的特定风险至关重要.
研究的目的:
- 在接种COVID-19疫苗后对GBS发病率进行系统审查和元分析.
- 在不同的疫苗技术中比较GBS风险,包括腺病毒载体和mRNA疫苗.
主要方法:
- 对调查COVID-19后GBS疫苗接种的队列研究进行系统审查和元分析.
- 使用随机效应模型计算GBS发病率和发病率比率.
- 根据疫苗技术和剂量数量分层分析.
主要成果:
- 亚地诺病毒载体疫苗的GBS发病率为每百万剂3.93例,而mRNA疫苗的0.69例.
- 第一剂COVID-19疫苗与GBS风险增加2.6倍有关.
- 腺病毒载体疫苗显示GBS风险增加2.37倍,而mRNA疫苗显示风险降低 (0.32倍).
结论:
- 与mRNA疫苗相比,亚地诺病毒载体COVID-19疫苗与GBS的风险明显更高.
- 用mRNA疫苗减少GBS风险可能与疫苗接种期间感染的减少有关.
- 腺病毒载体疫苗引发GBS的机制需要进一步研究.
更多相关视频
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
9.3K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.3K
相关概念视频
01:51Vaccinations
44.5K
Overview
44.5K
01:15Myasthenia Gravis: Diagnostic Tests
847
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
847
01:20Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K